Evidence map›Paper›PMID 34921323›Full record

ReviewDer Radiologe2022

[Positron emission tomography/computed tomography (PET/CT) in multiple myeloma].

Christos Sachpekidis, Hartmut Goldschmidt, Antonia Dimitrakopoulou-Strauss

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Radiologe, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 76% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Christos SachpekidisKlinische Kooperationseinheit Nuklearmedizin, Deutsches Krebsforschungszentrum (DKFZ), Im Neuenheimer Feld 280, 69210, Heidelberg, Deutschland. c.sachpekidis@dkfz-heidelberg.de.
Hartmut GoldschmidtSektion Multiples Myelom, Klinik für Hämatologie, Onkologie, Rheumatologie Heidelberg, Universitätsklinikum Heidelberg, Heidelberg, Deutschland.
Antonia Dimitrakopoulou-StraussKlinische Kooperationseinheit Nuklearmedizin, Deutsches Krebsforschungszentrum (DKFZ), Im Neuenheimer Feld 280, 69210, Heidelberg, Deutschland.
DKFZ-ZMBH Alliance · DEGerman Cancer Research Center · DEHeidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImaging plays a pivotal role in the management of multiple myeloma (MM). Besides morphological imaging methods, such as whole-body X‑ray, computed tomography (CT) and magnetic resonance imaging (MRI), the hybrid modality positron emission tomography/CT (PET/CT) using the glucose analogue

objectivesAim of this review article is to outline the major applications of PET/CT in the diagnosis and management of MM, and to provide hints on the reading and interpretation. MATERIALS AND

methodsBackground knowledge and guideline recommendations on imaging of MM are outlined and complemented by recent study results.

resultsAlthough

conclusionsPET/CT has a high value in the diagnosis, prognosis, and assessment of treatment response in patients with MM. Therefore, the role of the modality in the management of the disease is expected to increase in the near future.

Indexed as

Multiple MyelomaPositron Emission Tomography Computed TomographyFluorodeoxyglucose F18HumansMagnetic Resonance ImagingPositron-Emission TomographyRadiopharmaceuticalsFluorodeoxyglucose F18Radiopharmaceuticals18F‑FDGBone lesionsHybrid imagingInterpretationWhole body imaging

Identifiers

PMID34921323
OpenAlexW4200601705

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.